A large nationwide study in Denmark has found no evidence that aluminum exposure from childhood vaccines increases the risk of autoimmune, allergic, or neurodevelopmental disorders. The research, published in Annals of Internal Medicine, analyzed data from over 1.2 million children born between 1997 and 2018, providing robust evidence to address long-standing concerns about vaccine safety.
The study, conducted by researchers at the Statens Serum Institute, tracked children’s health outcomes based on their cumulative aluminum exposure from vaccines administered before age two. Using Denmark’s comprehensive health registries, the team examined 50 chronic disorders, including 36 autoimmune, 9 allergic, and 5 neurodevelopmental conditions.
Key findings revealed hazard ratios—a measure of risk—of 0.98 for autoimmune disorders, 0.99 for allergic conditions, and 0.93 for neurodevelopmental disorders per additional milligram of aluminum exposure. Notably, the risk for specific neurodevelopmental disorders like autism spectrum disorder (0.93) and ADHD (0.90) was slightly lower with increased aluminum exposure, though the study emphasizes this does not imply a protective effect.
“Our findings provide strong reassurance that aluminum-adsorbed vaccines do not contribute to the development of these chronic disorders,” said the lead author.
This study closes a critical gap in human data, reinforcing the safety of aluminum-containing vaccines. The results align with global health recommendations and may help alleviate parental concerns about childhood immunization. Future research could explore long-term outcomes beyond age five to further solidify these findings.
Add comment